

New Molecular Entities in Germany

Number



Source: Pharmazeutische Zeitung, vfa

In 2008, 31 pharmaceuticals based on NMEs (new molecular entities) were launched in the German market. Based on the global research process, the number of substances launched in Germany is closely connected to the international development of pharmaceuticals. Unless their importance is merely local, most new molecular entities receive marketing authorization in all key countries. This is the only way to balance the costs for the research and development of an NME, which globally amount to USD 800 million on average, within its limited patent term.